Tirzepatide 20MG (GLP-2 "TIRZ")
20MG Tirzepatide research vial. For Tirzepatide, each vial is labeled 20MG, molecular formula C225H348N48O68, molecular weight approx. 4,813.5 Da, CAS 2023788-19-2.
Published laboratory work with Tirzepatide has examined dual incretin receptor pharmacology, glucose and insulin signaling, adipose and hepatic metabolic pathway. Each lot is manufactured under sterile conditions, lyophilized in single-use research vials, and labeled with its production lot for traceability.
Supplied for in-vitro laboratory research use only. Not for human or veterinary consumption, administration, diagnostic or therapeutic use.
20MG research vial of Tirzepatide-class dual GIP/GLP-1 agonist for advanced metabolic pathway studies.
Background reading: Peptide Purity Testing and How to Read a Certificate of Analysis, HPLC vs Mass Spectrometry: What Each Test Actually Proves and Reconstitution and Storage Handling for Lyophilized Research Peptides.
These products are sold strictly for in-vitro laboratory research and are not intended for human consumption, diagnosis, treatment, or any therapeutic use. Purchaser must be 18 years of age or older and confirms they are a qualified researcher.
Compound identity
Listed on the storefront as GLP-2 "TIRZ". The verified compound identity for this research vial is below.
- Compound name
- Tirzepatide
- Also known as
- Tirzepatide, LY3298176, GLP-2 TIRZ, Dual GIP/GLP-1 agonist
- Molecular formula
- C225H348N48O68
- Molecular weight
- Approximately 4,813.5 Da
- CAS number
- 2023788-19-2
- Vial size
- 20MG
Product Information
Research DatasheetProduct Overview
20MG Tirzepatide research vial. A synthetic 39-amino acid dual GIP/GLP-1 receptor agonist used in laboratory research to investigate incretin biology, glucose homeostasis, insulin signaling, adipose metabolism, and dual receptor pharmacology. Manufactured under sterile conditions. For laboratory research use only. Not for human or veterinary use.
Molecular Profile
Research Applications
- ◆Dual incretin receptor pharmacology
- ◆Glucose and insulin signaling research
- ◆Adipose and hepatic metabolic pathway research
- ◆Energy homeostasis studies
- ◆Receptor binding and activation studies
- ◆Obesity and metabolic disease laboratory models
- ◆Peptide pharmacokinetics and stability research
- ◆Comparative incretin analog research
Quality Standards
For in-vitro research use only. Not for human consumption, diagnosis, or treatment.
20MG research vial of Tirzepatide-class dual GIP/GLP-1 agonist for advanced metabolic pathway studies. All ENOS research vials are lyophilized, sealed under sterile conditions, and shipped with cold-chain packaging where appropriate.
You may also like
GLP-3 "RET"
GLP-3 "RET" · 10MG
Next-gen tri-agonist studied for metabolic modulation.
GLP-3 "RET"
GLP-3 "RET" · 20MG
Higher-yield retatrutide research vial.
GLP-3 "RET"
GLP-3 "RET" · 60MG
Highest-yield retatrutide research vial.